Company: NCEL
Filing Date: 2025-10-24
Form Type: POS AM
Source: 0001213900-25-102149
Chunk: 6

Company: NewcelX Ltd.
Filing Date: 2025-10-24
Form: POS AM
Chunk 6
---
 Agreement (as defined below) provides that, upon the terms and subject to the conditions thereof, following the Closing (as
defined below), we shall work diligently to dispose of any Legacy Assets (as defined in the Merger Agreement), which excludes the Dual
Orexin Agonist platform (the “DOXA Platform”). The DOXA Platform includes AEX-041. It is important to note that AEX-041 is
currently in the preclinical stage of development. This means that the candidate is undergoing early laboratory studies to evaluate its
safety profile and pharmacological properties, and it has not yet been tested in human clinical trials. Consequently, its efficacy, safety
and potential for regulatory approval remain subject to further research and development.

We
were incorporated on June 10, 2015, as a Swiss limited company. Our registered office and principal executive office are located at The
Circle 6, 8058 Zurich, Switzerland. Our telephone number in Switzerland is +41.44.512.2150 and our website address is https://nlspharma.com.
The information contained on, or that can be accessed through, our website is not part of this prospectus. The website address has been
included in this prospectus solely as an inactive textual reference.

Common Shares Purchase Agreement with Alpha

On March 31, 2025, we
entered into the Purchase Agreement with the Selling Shareholder relating to a committed equity facility. Pursuant to the Purchase Agreement,
we have the right from time-to-time at our option to sell to the Selling Shareholder up to $25.0 million of Common Shares subject to
certain conditions and limitations set forth therein, and the Selling Shareholder is subject to a 9.99% beneficial ownership limitation.

Sales of the Common Shares
to the Selling Shareholder under the Purchase Agreement, and the timing of any sales, will be determined by us from time-to-time in our
sole discretion and will depend on a variety of factors, including, among other things, the market conditions and the trading price of
the Common Shares and determinations by us regarding the use of proceeds of such Common Shares. The net proceeds from any sales under
the Purchase Agreement will depend on the frequency with, and prices at which the Common Shares are sold to the Investor. We expect to
use the proceeds from any sales under the Purchase Agreement for working capital and general corporate purposes.

<div align='center'>1</div>

Upon the initial satisfaction
of the conditions to the